MathioudakisAG

Thank you to the @HCPLiveNews editorial team and @ChelsieDerman for the opportunity to discuss this work. 💡In a FLAME post-hoc analysis we found 3-month withdrawal effects on COPD exacerbations after ICS or LAMA discontinuation. 🔗 hcplive.com/view/copd-drug…

🫁 Stopping COPD inhalers can lead to higher risk of flare-ups for 3 months. Read about this Manchester BRC supported study led by Dr @MathioudakisAG in the February BRC news round-up 👇

📰 Stopping long-acting inhalers for COPD can lead to a sharp rise in flare-ups for 3 months, new research has revealed. The Manchester BRC-supported study was led by Dr @MathioudakisAG from our Respiratory Theme. 🫁 Read more 👇 manchesterbrc.nihr.ac.uk/news-and-event…

An innovative cancer screening programme in Greater Manchester has led to a 22% reduction in cases of late stage lung cancer. Researchers from our Cancer Prevention and Early Detection Theme were involved in the successful pilot study in Manchester. Read more👇 #WorldCancerDay

@ManchesterBRC @UoM_DIIIRM

Withdrawal effects are likely more common than we recognise and have been described across multiple drug classes (ICS, LAMA, beta-blockers, statins, anti-epileptics, etc). Greater vigilance is needed in both clinical trial design and everyday practice. 📄 thorax.bmj.com/content/early/…

Thank you to the @HCPLiveNews editorial team and @ChelsieDerman for the opportunity to discuss this work. 💡In a FLAME post-hoc analysis we found 3-month withdrawal effects on COPD exacerbations after ICS or LAMA discontinuation. 🔗 hcplive.com/view/copd-drug…

Enjoyed presenting our work on patient prioritised outcomes in COPD exacerbation trials at the outstanding @EuroRespSoc Seminar on airways disease exacerbations Thank you to the organisers for a fantastic and inspirational seminar

@SebastianBate @victoriachgr @DoctorJensUlrik @NawarBakerly @UoM_DIIIRM @ManchesterBRC

Why this matters: • Intermittent adherence may expose patients to avoidable short-term harm • Early withdrawal periods may bias RCT comparisons and subgroup analyses • Effects likely extend beyond standard 4-week run-in periods #COPD #ClinicalTrials

🫁📘 New in Thorax Stopping COPD maintenance inhalers is not neutral. In a post-hoc FLAME analysis, discontinuing LAMA or ICS was associated with a disproportionate early rise in exacerbations, concentrated in the first ~3 months — consistent with true withdrawal effects. 📊👇

🚀 Fully Funded PhD @OfficialUoM! Use big data & AI to detect COPD earlier and reduce #HealthInequalities. Train in #RespiratoryEpidemiology, #DigitalHealth, #Epidemiology & #DataScience Starts Oct 2026. 📩 Contact me for details findaphd.com/phds/project/b…

📢 Advancing Precision Medicine in Airway Diseases Dr Alexander Mathioudakis @MathioudakisAG is driving personalised care in COPD through data-driven research, identifying treatable traits and guiding therapies for maximal benefit. His work integrates large datasets, trial evidence, and emerging tools like AI and biologics to refine patient care. Read the full interview: touchrespiratory.com/insight/advanc… #COPD #PrecisionMedicine #RespiratoryResearch

Reduced treatment response to inhaled corticosteroids in current smokers with COPD, regardless of blood eosinophil count: insights from the FLAME trial. thorax.bmj.com/content/80/9/6… @mathioudakisag

📢 Future Leaders 2025 – Dr Alexander G. Mathioudakis We’re proud to spotlight Dr Alexander Mathioudakis, Senior Lecturer at The University of Manchester and Consultant Respiratory Physician, as a touchRESPIRATORY Future Leader 2025. 🌍🫁 Read Q&A: 👉 touchrespiratory.com/insight/advanc…

The new European Respiratory Journal impact factor is 21. Ranked #2 across all resp journals Thank you to the incredible @donsin4 , all authors, our outstanding editors and journal staff ♥️ @ERSpublications @EuroRespSoc IF for selected respiratory journals below

We are pleased to announced our new 2024 Journal Impact Factors: European Respiratory Journal, 21.0 (Q1) European Respiratory Review, 10.4 (Q1) ERJ Open Research, 4.0 (Q1) Breathe, 3.4 (Q2) Thank you to all our editors for their work to achieve these!

📅ERS President Prof. Silke Ryan has opened the ‘ERS Presidential Summit on Prevention: Improving Respiratory Health in Europe’ – welcoming both professional/patient stakeholders for an in-depth look at respiratory disease prevention.

👉 Ex-smokers with high BEC (≥200) do benefit from LABA+ICS 🚭 But current smokers? Minimal ICS response. 📊 Smoking status modifies ICS efficacy @JensUlrikJensen @victoriachgr @ManchesterBRC @UoM_DIIIRM

🔥 Our new analysis from the #FLAMEtrial - just published @ThoraxBMJ: 📉 Reduced treatment response to inhaled corticosteroids in current smokers with COPD, regardless of blood eosinophil count: Insights from the FLAME trial. thorax.bmj.com/content/early/…

It was a great pleasure to speak about career pathways in airway diseases at the @RSMResp #CareersDay. Great event! Thank you @RSMResp and @DrSachinAnanth for the invitation!